How to improve the outcomes of elderly acute myeloid leukemia patients through allogeneic hematopoietic stem cell transplantation

Front Immunol. 2023 May 3:14:1102966. doi: 10.3389/fimmu.2023.1102966. eCollection 2023.

Abstract

In recent years, with the gradual advancement of haploidentical transplantation technology, the availability of donors has increased significantly, along with the widespread use of reduced-intensity conditioning and the improvement of nursing techniques, giving more elderly acute myeloid leukemia (AML) patients the chance to receive allogeneic hematopoietic stem cell transplantation. We have summarized the classic and recently proposed pre-transplant assessment methods and assessed the various sources of donors, conditioning regimens, and post-transplant complication management based on the outcomes of large-scale clinical studies for elderly AML patients.

Keywords: GvHD; acute myeloid leukaemia (AML); allogeneic hematopoietic cell transplantation; conditioning regimen; elderly patients; relapse.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Graft vs Host Disease* / etiology
  • Hematopoietic Stem Cell Transplantation* / adverse effects
  • Humans
  • Leukemia, Myeloid, Acute* / etiology
  • Leukemia, Myeloid, Acute* / therapy
  • Retrospective Studies
  • Transplantation, Haploidentical

Grants and funding

This review was funded by the Natural Science Foundation and Natural Science Foundation of Hubei Province (grant numbers 2020CBF772 and 2020CBF790). This review was supported by the Collaborative Innovation Center of Hematology of China.